RxDoctor Payments Data

Landon Church, APRN

Nurse Practitioner · Nashville, TNNPI 1164021556

Payments from drug & device makers

$7,459in general payments, 2019–2025

Across 251 payments — averaging $29.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Pfizer$1K
  • Abiomed$419
  • AstraZeneca$283
  • Amgen$251
  • Johnson & Johnson$244
  • plus $2K from 25 others
$122in research payments, 2019–2025

Across 1 payment — averaging $121.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$122

What the payments were for

  • Travel & lodging$89112%
  • Food & beverage$6,48487%
  • Education$831%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,459 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$2,844
Medicare patients
23
Services billed
43

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan59$39,682
FarxigaDapagliflozin Propanediol51$32,681
EliquisApixaban22$16,353
Atorvastatin Calcium83$738
Torsemide45$581
ClopidogrelClopidogrel Bisulfate46$479
Metoprolol Succinate38$392
Spironolactone71$373
Potassium Chloride19$212
Losartan Potassium19$186
Rosuvastatin Calcium15$175
Amlodipine Besylate32$150
Carvedilol29$126
Amiodarone Hcl17$121
Furosemide40$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$173$39,68259 claims
AstraZenecaFarxiga$283$32,68151 claims
PfizerEliquis$1,084$16,35322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →